{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:37Z","timestamp":1793324797160,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Neovascular glaucoma (NVG) is characterised by neovascularisation of the angle and therefore elevated intraocular pressure (IOP). This results in progressive optic neuropathy and loss of visual acuity. Treatment aims to reduce IOP in order to prevent optic nerve damage. A systematic review was completed synthesising results from randomised control trials (RCTs) comparing interventions for the management of NVG and their efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data was sourced from Web of Science, Embase and Medline after 1st January 2000. The primary outcome measures were mean IOP at follow-up and success rate. The secondary outcomes included mean IOP lowering medications and total complications. A meta-analysis was completed on comparative studies using Revman (version 5.4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For the two studies comparing Ahmed glaucoma valve (AGV)\u2009+\u2009pan-retinal photocoagulation (PRP) vs AGV\u2009+\u2009PRP\u2009+\u2009intra-vitreal bevacizumab (IVB), there was no difference in mean IOP or odds of success from the meta-analysis. From the 4 studies examining the utilisation of anti-vascular endothelial growth factor (anti-VEGF), one study showed lower mean IOP at 1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and 3\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033) for IVB vs sham injection. In the 2 studies studying transcleral diode laser (TDL), there were no significant findings. From the 4 studies looking at trabeculectomy (trab), lower mean IOP at 6 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), 9 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), 12 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and 18\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) was shown for intra-vitreal ranibizumab (IVR)\u2009+\u2009PRP\u2009+\u2009visco-trabeculectomy vs IVR\u2009+\u2009PRP\u2009+\u2009trab, and a significantly lower mean IOP was present in the Baerveldt group vs trab at 6\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). In the 2 studies investigating the AGV, there was a lower mean IOP at 1\u00a0month (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) in the AGV\u2009+\u2009triamcinolone (TCA) group. The risk of bias was low for 4 studies, high for 4 studies and 6 studies had some concerns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first meta-analysis of RCTs in the management of neovascular glaucoma. The lack of high-quality evidence contributes to the lack of consensus in managing NVG. Our results highlight modern treatment strategies and the need for better powered RCTs with long-term follow-up in order to establish optimal treatment modalities and true patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-022-05785-5","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T02:03:38Z","timestamp":1659924218000},"page":"477-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice"],"prefix":"10.1007","volume":"261","author":[{"given":"Saajan","family":"Ramji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurnoor","family":"Nagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdus Samad","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6623-1720","authenticated-orcid":false,"given":"Obeda","family":"Kailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"issue":"2","key":"5785_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08820530902800801","volume":"24","author":"TA Shazly","year":"2009","unstructured":"Shazly TA, Latina MA (2009) Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 24(2):113\u2013121. https:\/\/doi.org\/10.1080\/08820530902800801","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"5785_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.preteyeres.2007.06.001","volume":"26","author":"SS Hayreh","year":"2007","unstructured":"Hayreh SS (2007) Neovascular glaucoma. Prog Retin Eye Res 26(5):470\u2013485. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.06.001","journal-title":"Prog Retin Eye Res"},{"issue":"22","key":"5785_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480\u20131487. https:\/\/doi.org\/10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"issue":"8","key":"5785_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114(8):964\u2013970. https:\/\/doi.org\/10.1001\/archopht.1996.01100140172010","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"5785_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamaophthalmol.2014.2356","volume":"132","author":"KV Chalam","year":"2014","unstructured":"Chalam KV, Brar VS, Murthy RK (2014) Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol 132(11):1350\u20131354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2356","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"5785_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/s0161-6420(01)00775-8","volume":"108","author":"JA Sivak-Callcott","year":"2001","unstructured":"Sivak-Callcott JA, O\u2019Day DM, Gass JD, Tsai JC (2001) Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108(10):1767\u20131800. https:\/\/doi.org\/10.1016\/s0161-6420(01)00775-8","journal-title":"Ophthalmology"},{"issue":"6","key":"5785_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00417-019-04256-8","volume":"257","author":"Z Shchomak","year":"2019","unstructured":"Shchomak Z, Cordeiro Sousa D, Leal I, Abeg\u00e3o Pinto L (2019) Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol 257(6):1079\u20131089. https:\/\/doi.org\/10.1007\/s00417-019-04256-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5785_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2022.095","author":"D Parkash","year":"2022","unstructured":"Parkash D, Gohil A, Ansari AS, Kulkarni A, Kailani O (2022) Trends in glaucoma surgery: an evolving landscape. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/j.1755-3768.2022.095","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"5785_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5005\/jp-journals-10008-1168","volume":"8","author":"A Hernandez-Oteyza","year":"2014","unstructured":"Hernandez-Oteyza A, Lazcano-Gomez G, Jimenez-Roman J, Hernandez-Garciadiego C (2014) Surgical outcome of ahmed valve implantation in mexican patients with neovascular glaucoma. J Curr Glaucoma Pract 8(3):86\u201390. https:\/\/doi.org\/10.5005\/jp-journals-10008-1168","journal-title":"J Curr Glaucoma Pract"},{"issue":"7","key":"5785_CR10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/bjo.83.7.814","volume":"83","author":"H Mietz","year":"1999","unstructured":"Mietz H, Raschka B, Krieglstein GK (1999) Risk factors for failures of trabeculectomies performed without antimetabolites. Br J Ophthalmol 83(7):814\u2013821. https:\/\/doi.org\/10.1136\/bjo.83.7.814","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"5785_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IIO.0b013e31821e5960","volume":"51","author":"LC Olmos","year":"2011","unstructured":"Olmos LC, Lee RK (2011) Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin 51(3):27\u201336. https:\/\/doi.org\/10.1097\/IIO.0b013e31821e5960","journal-title":"Int Ophthalmol Clin"},{"key":"5785_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2022.091","author":"E Lee","year":"2022","unstructured":"Lee E, Ansari AS, Nagi G, Ramji S, Jackson T, Kailani O (2022) Evaluating variance in the medical and surgical management of neovascular glaucoma. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/j.1755-3768.2022.091","journal-title":"Acta Ophthalmol"},{"key":"5785_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan \u2014 a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"5785_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj\/I4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj\/I4898","journal-title":"BMJ"},{"issue":"7650","key":"5785_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"9","key":"5785_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/IJG.0b013e318259aec4","volume":"22","author":"RA Mahdy","year":"2013","unstructured":"Mahdy RA, Nada WM, Fawzy KM, Alnashar HY, Almosalamy SM (2013) Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. J Glaucoma 22(9):768\u2013772. https:\/\/doi.org\/10.1097\/IJG.0b013e318259aec4","journal-title":"J Glaucoma"},{"issue":"1","key":"5785_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/aos.12493","volume":"93","author":"ES Arcieri","year":"2015","unstructured":"Arcieri ES, Paula JS, Jorge R, Barella KA, Arcieri RS, Secches DJ, Costa VP (2015) Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmol 93(1):1\u20136. https:\/\/doi.org\/10.1111\/aos.12493","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"5785_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.5301\/ejo.5000089","volume":"22","author":"E Wittstr\u00f6m","year":"2012","unstructured":"Wittstr\u00f6m E, Holmberg H, Hvarfner C, Andr\u00e9asson S (2012) Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. Eur J Ophthalmol 22(4):563\u2013574. https:\/\/doi.org\/10.5301\/ejo.5000089","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"5785_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s12325-020-01579-5","volume":"38","author":"M Inatani","year":"2021","unstructured":"Inatani M, Higashide T, Matsushita K, Miki A, Ueki M, Iwamoto Y, Kobayashi M, Leal S, Investigators VEGA (2021) Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Adv Ther 38(2):1116\u20131129. https:\/\/doi.org\/10.1007\/s12325-020-01579-5","journal-title":"Adv Ther"},{"issue":"8","key":"5785_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","volume":"18","author":"S Yazdani","year":"2009","unstructured":"Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M (2009) Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 18(8):632\u2013637. https:\/\/doi.org\/10.1097\/IJG.0b013e3181997211","journal-title":"J Glaucoma"},{"issue":"8","key":"5785_CR21","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s10792-021-01846-6","volume":"41","author":"X Guo","year":"2021","unstructured":"Guo X, Wang Y, Yang L, Wang P, Chen K, Zhou L, Wu Y (2021) Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma. Int Ohthalmol 41(8):2869\u20132877. https:\/\/doi.org\/10.1007\/s10792-021-01846-6","journal-title":"Int Ohthalmol"},{"key":"5785_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3781249","volume":"107","author":"FM Wagdy","year":"2020","unstructured":"Wagdy FM, Zaky AG (2020) Comparison between the express implant and transscleral diode laser in neovascular glaucoma. J Ophthalmol 107:1\u20136. https:\/\/doi.org\/10.1155\/2020\/3781249","journal-title":"J Ophthalmol"},{"key":"5785_CR23","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2147\/OPTH.S188999","volume":"12","author":"B Choy","year":"2018","unstructured":"Choy B, Lai J, Yeung J, Chan J (2018) Randomized comparative trial of diode laser transscleral cyclophotocoagulation versus Ahmed glaucoma valve for neovascular glaucoma in Chinese - a pilot study. Clin Ophthalmol 12:2545\u20132552. https:\/\/doi.org\/10.2147\/OPTH.S188999","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"5785_CR24","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00417-021-05257-2","volume":"259","author":"K Tokumo","year":"2021","unstructured":"Tokumo K, Komatsu K, Yuasa Y, Murakami Y, Okumichi H, Hirooka K, Nakakura S, Tabuchi H, Kiuchi Y (2021) Treatment outcomes in the neovascular glaucoma tube versus trabeculectomy study. Graefes Arch Clin Exp Ophthalmol 259(10):3067\u20133076. https:\/\/doi.org\/10.1007\/s00417-021-05257-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"5785_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/APO.0000000000000248","volume":"8","author":"AS Elwehidy","year":"2019","unstructured":"Elwehidy AS, Bayoumi N, Badawi AE, Hagras SM, Abdelkader A (2019) Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila) 8(4):308\u2013313. https:\/\/doi.org\/10.1097\/APO.0000000000000248","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"3","key":"5785_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1600-0420.2006.00810.x","volume":"85","author":"D Sisto","year":"2007","unstructured":"Sisto D, Vetrugno M, Trabucco T, Cantatore F, Ruggeri G, Sborgia C (2007) The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand 85(3):267\u2013271. https:\/\/doi.org\/10.1111\/j.1600-0420.2006.00810.x","journal-title":"Acta Ophthalmol Scand"},{"issue":"3","key":"5785_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/112067210901900318","volume":"19","author":"V Gupta","year":"2009","unstructured":"Gupta V, Jha R, Rao A, Kong G, Sihota R (2009) The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 19(3):435\u2013441. https:\/\/doi.org\/10.1177\/112067210901900318","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"5785_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/IJG.0b013e31820d7e4e","volume":"21","author":"SH Teixeira","year":"2012","unstructured":"Teixeira SH, Doi LM, Freitas Silva AL, Silva KD, Paes AT, Higa FS, Mendon\u00e7a M, Prata JA, Paranhos A (2012) Silicone Ahmed glaucoma valve with and without intravitreal triamcinolone acetonide for neovascular glaucoma: randomized clinical trial. J Glaucoma 21(5):342\u20138. https:\/\/doi.org\/10.1097\/IJG.0b013e31820d7e4e","journal-title":"J Glaucoma"},{"issue":"8","key":"5785_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjo.87.8.994","volume":"87","author":"R Susanna Jr","year":"2003","unstructured":"Susanna R Jr, Latin American Glaucoma Society Investigators (2003) Partial Tenon\u2019s capsule resection with adjunctive mitomycin C in Ahmed glaucoma valve implant surgery. Br J Ophthalmol 87(8):994\u2013998. https:\/\/doi.org\/10.1136\/bjo.87.8.994","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"5785_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/IJG.0000000000000241","volume":"25","author":"M Zhou","year":"2016","unstructured":"Zhou M, Xu X, Zhang X, Sun X (2016) Clinical outcomes of ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. J Glaucoma 25(7):551\u2013557. https:\/\/doi.org\/10.1097\/IJG.0000000000000241","journal-title":"J Glaucoma"},{"issue":"4","key":"5785_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/jop.2014.0108","volume":"31","author":"HB Hwang","year":"2015","unstructured":"Hwang HB, Han JW, Yim HB, Lee NY (2015) Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. J Ocul Pharmacol Ther 31(4):198\u2013203. https:\/\/doi.org\/10.1089\/jop.2014.0108","journal-title":"J Ocul Pharmacol Ther"},{"key":"5785_CR32","doi-asserted-by":"publisher","unstructured":"Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB (2020) Anti\u2010vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews, Issue 2, Art. No: CD007920. https:\/\/doi.org\/10.1002\/14651858.CD007920.pub3","DOI":"10.1002\/14651858.CD007920.pub3"},{"issue":"2","key":"5785_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2014.08.043","volume":"122","author":"DL Budenz","year":"2015","unstructured":"Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM, The Ahmed Baerveldt Comparison Study Group (2015) Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology 122(2):308\u2013316. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.043","journal-title":"Ophthalmology"},{"issue":"10","key":"5785_CR34","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.ophtha.2016.06.035","volume":"123","author":"PG Christakis","year":"2016","unstructured":"Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, Mura JJ, Cantor LB, Ahmed IIK (2016) The Ahmed versus baerveldt study: five-year treatment outcomes. Ophthalmology 123(10):2093\u20132102. https:\/\/doi.org\/10.1016\/j.ophtha.2016.06.035","journal-title":"Ophthalmology"},{"issue":"10","key":"5785_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/IJG.0000000000001912","volume":"30","author":"M Ibarz Barbera","year":"2021","unstructured":"Ibarz Barbera M, Morales-Fernandez L, G\u00f3mez de Lia\u00f1o R, Ta\u00f1\u00e1 Rivero P, Teus MA (2021) Changes to corneal topography and biometrics after PRESERFLO microshunt surgery for glaucoma. J Glaucoma 30(10):921\u2013993. https:\/\/doi.org\/10.1097\/IJG.0000000000001912","journal-title":"J Glaucoma"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05785-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:13:51Z","timestamp":1673507631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05785-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5785"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05785-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. As confirmed by the Medical Research Council (MRC) NHS Health Research Authority Decision Tool, ethical approval was not required, as this study retrieved and synthesised data from already published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}